GRDN is the ticker symbol for Guardian Pharmacy Services, Inc., a publicly traded Healthcare sector company listed on NYSE. 13F Pro tracks GRDN with AI-powered analysis, an AI quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is GRDN a good stock to buy?

13F Pro's AI ranking engine scores GRDN at 62.0/100, ranked #741 of 2,925 stocks on a composite quality score built from its SEC filings, covering profitability, growth, balance sheet strength, and free cash flow. The full AI verdict and bull/bear case for GRDN is available at https://13fpro.ai/company/GRDN. Not investment advice — review the underlying SEC filings before making any trade.

Where does 13F Pro source GRDN data?

All Guardian Pharmacy Services, Inc. fundamentals and ownership data come directly from SEC EDGAR. Guardian Pharmacy Services, Inc. files with the SEC under CIK 1802255. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

Guardian Pharmacy Services, Inc. GRDN

NYSEMid CapHealthcare

13F Pro quality score

Rank #741 of 2,925TOP 50%

Why it scores 62 Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$351.77M

Quarter to Jun 30

Net income

$21.87M

Quarter to Jun 30

Operating margin

5.9%

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026

$1.23B total

FMR LLC

$135.73M+37.4%

WELLINGTON MANAGEMENT GROUP LLP

$72.39M-2.0%

BlackRock, Inc.

$65.99M-10.3%

VANGUARD CAPITAL MANAGEMENT LLC

$57.77M+12.6%

Woodline Partners LP

$54.70M0.0%

Valiant Capital Management, L.P.

$49.69M0.0%

T. Rowe Price Investment Management, Inc.

$46.76M+8.6%

Boston Partners

$40.80M-3.3%

FRANKLIN RESOURCES INC

$40.46M+1.4%

TimesSquare Capital Management, LLC

$39.85M-11.7%

LOOMIS SAYLES & CO L P

$36.42M-6.6%

BOONE CAPITAL MANAGEMENT LLC

$29.81M+12.8%

GEODE CAPITAL MANAGEMENT, LLC

$27.08M+15.7%

JENNISON ASSOCIATES LLC

$26.24M-23.8%

STATE STREET CORP

$24.71M+15.9%

BESSEMER GROUP INC

$22.95M+596.7%

BROWN ADVISORY INC

$21.94M-58.4%

DIMENSIONAL FUND ADVISORS LP

$21.61M+147.4%

DRIEHAUS CAPITAL MANAGEMENT LLC

$21.36M-13.4%

FIRST TRUST ADVISORS LP

$19.31M+392.4%

Aristotle Capital Boston, LLC

$17.69M-14.8%

SILVERCREST ASSET MANAGEMENT GROUP LLC

$14.45M-7.9%

ACADIAN ASSET MANAGEMENT LLC

$14.29M+75.2%

BRAUN STACEY ASSOCIATES INC

$14.23MNew

MORGAN STANLEY

$13.06M+166.7%

See all 188 institutional holders →

What's Driving GRDN's Business? Latest 10-Q Breakdown

18/18 datapoints verified

AI-extracted from the 10-Q filed 2026-08-06 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Revenue grew a modest 2.2% YoY to $351.8M as IRA-driven Medicare Part D price cuts offset acquisition and volume gains, while an $8.5M one-time legal settlement helped push net income to $22.1M.

Biggest Revenue Drivers

2025 Acquisitions+$13.3M

Incremental revenue contributed by pharmacy operations acquired during 2025

Organic revenue-$5.9M

Decreased primarily due to Inflation Reduction Act Medicare Part D price reductions, despite residents served rising to ~210,000 and prescriptions dispensed rising to 7.6 million

Biggest Revenue Drivers

Total revenue: $351.8M+2.2% YoY

2025 Acquisitions+$13.3M

Incremental revenue contributed by pharmacy operations acquired during 2025

Organic revenue-$5.9M

Decreased primarily due to Inflation Reduction Act Medicare Part D price reductions, despite residents served rising to ~210,000 and prescriptions dispensed rising to 7.6 million

Largest Expense Items

Cost of goods sold$271.7M-1.6% YoY

Decreased primarily due to product cost decreases from IRA drug pricing reforms, partly offset by $11.3M added from 2025 Acquisitions

Selling, general, and administrative expenses$59.4M+6.9% YoY

Increase driven by higher average employee headcount ($2.2M organic, $1.6M from 2025 Acquisitions)

Provision for income taxes$7.7M+104.0% YoY

Higher pre-tax income, partly offset by a lower effective tax rate (25.7% vs 29.9%) from a smaller IPO-related share-based compensation charge

Margins: Cost of goods sold fell from 80.2% to 77.2% of revenue on IRA-driven product cost decreases, but SG&A rose from 16.1% to 16.9% of revenue as expense growth outpaced revenue growth.

Watch Items from the Filing

Company expects IRA-related Medicare Part D price reductions to continue impacting year-over-year revenue and cost comparability throughout the remainder of 2026.
An $8.5 million one-time payor-reimbursement settlement (received April 21, 2026) drove most of the swing in Other expense (income), inflating net income to $22.1M versus $8.8M a year ago.
Residents served grew from 195,000 to 210,000 and prescriptions dispensed rose from 7.0M to 7.6M YoY, showing underlying volume growth despite pricing headwinds.
All revenue and long-lived assets are generated/held solely in the United States, with the company operating as a single reportable segment.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →

Key Metrics

Revenue

Q2 2026

EDGAR

Net Income

Q2 2026

EDGAR

Operating Margin

Q2 2026

EDGAR

ROIC

Q2 2026

EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/GRDN

Loading ratio trend…

Guardian Pharmacy Services, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Op. marginOperating margin
FY 2025	10-K	$1.4B	$49.2M	5.0%
FY 2024	10-K	$1.2B	$-110.0M	-5.1%

About Guardian Pharmacy Services, Inc. (GRDN): stock profile, AI score and financials

Guardian Pharmacy Services, Inc. (GRDN) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores GRDN at 62.0/100 on a composite quality score built from its SEC filings, placing it at rank #741 of 2,925 stocks — the top half of the AI-ranked universe. GRDN scores in the top quartile across balance sheet strength (94.2). Based on the latest XBRL financial filings (Q2 2026), Guardian Pharmacy Services, Inc. reports quarterly revenue of $351.8M, net income of $21.9M, an operating margin of 5.9%. Top institutional holders of GRDN by reported 13-F value include FMR, WELLINGTON MANAGEMENT GROUP LLP, BlackRock, based on the most recent SEC filings. GRDN trades on the NYSE exchange and files with the SEC under CIK 1802255. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GRDN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Guardian Pharmacy Services, Inc. directly from SEC EDGAR.

Financials through the period ended Jun 30, 2026SEC EDGAR: CIK 1802255 →

Guardian Pharmacy Services, Inc. GRDN

Top Institutional Holders

What's Driving GRDN's Business? Latest 10-Q Breakdown

Biggest Revenue Drivers

Biggest Revenue Drivers

Largest Expense Items

Watch Items from the Filing

Key Metrics

Financial Trends

Revenue & Net Income

GRDN key financials by period

GRDN insiders

About Guardian Pharmacy Services, Inc. (GRDN): stock profile, AI score and financials

Guardian Pharmacy Services, Inc. GRDN

Top Institutional Holders

What's Driving GRDN's Business? Latest 10-Q Breakdown

Biggest Revenue Drivers

Key Metrics

Financial Trends

Revenue & Net Income

GRDN key financials by period

Companies similar to GRDN

GRDN insiders

About Guardian Pharmacy Services, Inc. (GRDN): stock profile, AI score and financials